Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman
2 Views
administrator
07/30/23
A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd
-
Category
Show more
Facebook Comments
No comments found